Impact of the timing of hepatitis B virus identification and anti –hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy

CONCLUSIONSEarly identification correlates with early anti‐HBV therapy and reduces the risk of liver failure and death in chronic HBV patients receiving chemotherapy. Cancer 2017. © 2017 American Cancer Society.

Source: Cancer - May 18, 2017 Category: Cancer & Oncology Authors: Jessica P. Hwang, Maria E. Suarez ‐Almazor, Scott B. Cantor, Andrea Barbo, Heather Y. Lin, Sairah Ahmed, Mariana Chavez‐MacGregor, Christian Donato‐Santana, Cathy Eng, Alessandra Ferrajoli, Michael J. Fisch, Peter McLaughlin, George R. Simon, Gabrie Tags: Original Article Source Type: research